• Je něco špatně v tomto záznamu ?

Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis

K. Furuta, Q. Guo, KD. Pavelko, JH. Lee, KD. Robertson, Y. Nakao, J. Melek, VH. Shah, P. Hirsova, SH. Ibrahim

. 2021 ; 131 (6) : . [pub] 20210315

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025965

Grantová podpora
P30 DK084567 NIDDK NIH HHS - United States
R01 DK122948 NIDDK NIH HHS - United States

Monocyte homing to the liver and adhesion to the liver sinusoidal endothelial cells (LSECs) are key elements in nonalcoholic steatohepatitis (NASH) pathogenesis. We reported previously that VCAM-1 mediates monocyte adhesion to LSECs. However, the pathogenic role of VCAM-1 in NASH is unclear. Herein, we report that VCAM-1 was a top upregulated adhesion molecule in the NASH mouse liver transcriptome. Open chromatin landscape profiling combined with genome-wide transcriptome analysis showed robust transcriptional upregulation of LSEC VCAM-1 in murine NASH. Moreover, LSEC VCAM-1 expression was significantly increased in human NASH. LSEC VCAM-1 expression was upregulated by palmitate treatment in vitro and reduced with inhibition of the mitogen-activated protein 3 kinase (MAP3K) mixed lineage kinase 3 (MLK3). Likewise, LSEC VCAM-1 expression was reduced in the Mlk3-/- mice with diet-induced NASH. Furthermore, VCAM-1 neutralizing Ab or pharmacological inhibition attenuated diet-induced NASH in mice, mainly via reducing the proinflammatory monocyte hepatic population as examined by mass cytometry by time of flight (CyTOF). Moreover, endothelium-specific Vcam1 knockout mice were also protected against NASH. In summary, lipotoxic stress enhances the expression of LSEC VCAM-1, in part, through MLK3 signaling. Inhibition of VCAM-1 was salutary in murine NASH and might serve as a potential therapeutic strategy for human NASH.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025965
003      
CZ-PrNML
005      
20211118094834.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1172/JCI143690 $2 doi
035    __
$a (PubMed)33476308
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Furuta, Kunimaro $u Division of Gastroenterology and Hepatology
245    10
$a Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis / $c K. Furuta, Q. Guo, KD. Pavelko, JH. Lee, KD. Robertson, Y. Nakao, J. Melek, VH. Shah, P. Hirsova, SH. Ibrahim
520    9_
$a Monocyte homing to the liver and adhesion to the liver sinusoidal endothelial cells (LSECs) are key elements in nonalcoholic steatohepatitis (NASH) pathogenesis. We reported previously that VCAM-1 mediates monocyte adhesion to LSECs. However, the pathogenic role of VCAM-1 in NASH is unclear. Herein, we report that VCAM-1 was a top upregulated adhesion molecule in the NASH mouse liver transcriptome. Open chromatin landscape profiling combined with genome-wide transcriptome analysis showed robust transcriptional upregulation of LSEC VCAM-1 in murine NASH. Moreover, LSEC VCAM-1 expression was significantly increased in human NASH. LSEC VCAM-1 expression was upregulated by palmitate treatment in vitro and reduced with inhibition of the mitogen-activated protein 3 kinase (MAP3K) mixed lineage kinase 3 (MLK3). Likewise, LSEC VCAM-1 expression was reduced in the Mlk3-/- mice with diet-induced NASH. Furthermore, VCAM-1 neutralizing Ab or pharmacological inhibition attenuated diet-induced NASH in mice, mainly via reducing the proinflammatory monocyte hepatic population as examined by mass cytometry by time of flight (CyTOF). Moreover, endothelium-specific Vcam1 knockout mice were also protected against NASH. In summary, lipotoxic stress enhances the expression of LSEC VCAM-1, in part, through MLK3 signaling. Inhibition of VCAM-1 was salutary in murine NASH and might serve as a potential therapeutic strategy for human NASH.
650    _2
$a zvířata $7 D000818
650    _2
$a neutralizující protilátky $x aplikace a dávkování $7 D057134
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a endoteliální buňky $x účinky léků $x metabolismus $7 D042783
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a játra $x účinky léků $x metabolismus $x patologie $7 D008099
650    _2
$a MAP kinasový signální systém $x účinky léků $7 D020935
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a nealkoholová steatóza jater $x etiologie $x genetika $x metabolismus $7 D065626
650    _2
$a palmitany $x toxicita $7 D010168
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a upregulace $x účinky léků $7 D015854
650    _2
$a cévní buněčněadhezivní molekula-1 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D019010
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Guo, Qianqian $u Division of Gastroenterology and Hepatology
700    1_
$a Pavelko, Kevin D $u Department of Immunology
700    1_
$a Lee, Jeong-Heon $u Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, and
700    1_
$a Robertson, Keith D $u Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Nakao, Yasuhiko $u Division of Gastroenterology and Hepatology
700    1_
$a Melek, Jan $u Department of Pediatrics, Charles University in Prague, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové, Czechia $7 xx0264012
700    1_
$a Shah, Vijay H $u Division of Gastroenterology and Hepatology
700    1_
$a Hirsova, Petra $u Division of Gastroenterology and Hepatology
700    1_
$a Ibrahim, Samar H $u Division of Gastroenterology and Hepatology $u Division of Pediatric Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA
773    0_
$w MED00002590 $t The Journal of clinical investigation $x 1558-8238 $g Roč. 131, č. 6 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33476308 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211118094837 $b ABA008
999    __
$a ok $b bmc $g 1714851 $s 1146472
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 131 $c 6 $e 20210315 $i 1558-8238 $m The Journal of clinical investigation $n J Clin Invest $x MED00002590
GRA    __
$a P30 DK084567 $p NIDDK NIH HHS $2 United States
GRA    __
$a R01 DK122948 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...